Trinity Biotech
TRIB
93 hedge funds and large institutions have $260M invested in Trinity Biotech in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0% more funds holding
Funds holding: 93 → 93 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
18% less capital invested
Capital invested by funds: $318M → $260M (-$58.3M)
24% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $2.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$4.5M |
| 2 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$3.34M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.94M |
| 4 |
SC
Skylands Capital
Milwaukee,
Wisconsin
|
+$2.68M |
| 5 |
PIM
Paradice Investment Management
Denver,
Colorado
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.3M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$4.53M |
| 3 |
VAM
Visium Asset Management
New York
|
-$3.46M |
| 4 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$2.5M |
| 5 |
TCM
Tygh Capital Management
Portland,
Oregon
|
-$1.33M |
TRIB Hedge Fund Activity: Q3 2014 in Review
93 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2014, worth a combined $260M — down 18% from $318M a quarter earlier.
Fund positioning in TRIB was balanced in Q3 2014: 11 funds opened new positions, 11 closed out, 39 added to existing stakes and 29 trimmed.
The largest buyer was Northern Trust, adding an estimated $4.5M. The largest seller was Fidelity Investments, exiting entirely with an estimated $9.3M sold.
- 93 institutional investors held Trinity Biotech (TRIB) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $260M of Trinity Biotech stock for Q3 2014, down 18% quarter-over-quarter.
- 11 funds opened new Trinity Biotech positions in Q3 2014 and 11 closed out, a net change of 0 holders.
- The largest Trinity Biotech buyer in Q3 2014 was Northern Trust, an estimated $4.5M added.
- The largest Trinity Biotech seller in Q3 2014 was Fidelity Investments, an estimated $9.3M sold.
Based on aggregated 13F filings for Q3 2014.